Earlier this year, BioDuro announced a joint venture with Cenra API Solutions, a Taiwan-based API manufacturer with more than six decades of experience. The collaboration added 10 GMP API production lines and more than 350,000 liters of reactor capacity to BioDuro’s global network, connecting process development with clinical and commercial-scale manufacturing.

At CPHI Milan, Qixuan Lu, Senior Vice President of Process Chemistry at BioDuro, will discuss how this integrated model supports API programs from early development through commercial manufacturing. In this Q&A, he explains how the two teams work together and what the model offers clients planning for scale-up and commercial supply.

Q1: What is the vision behind the BioDuro–Cenra joint venture?

The BioDuro-Cenra joint venture was established to close a critical gap in the drug development ecosystem by seamlessly integrating early-stage discovery and process development with large-scale GMP manufacturing.

By combining BioDuro’s expertise in process development, analytical method development, and Registered Starting Material (RSM) sourcing with Cenra API Solutions’ proven large-scale GMP manufacturing capabilities, the partnership creates a unified pathway from early development through commercial production.

Our differentiated business model defines clear yet complementary roles: BioDuro serves as the Process Analytical Developer, owning process and analytical development, technology transfer, and regulatory filing preparation. Cenra operates as the Process Analytical Receiver, taking full ownership of post-transfer commercial manufacturing. To ensure seamless execution, BioDuro deploys on-site technical teams to Cenra’s manufacturing facilities, providing real-time oversight, troubleshooting support, and quality assurance throughout the production lifecycle.

The ultimate goal is to offer biopharma innovators a single-source, end-to-end solution that eliminates traditional handoff friction and accelerates time-to-market.

Q2: How does this collaboration benefit biopharma companies?

Emerging biotech companies frequently struggle to identify partners capable of supporting both early-stage flexibility and commercial-scale reliability without compromising speed or quality. The BioDuro-Cenra model addresses this challenge through a unified client interface and integrated project management framework.

Key advantages include:

• Accelerated program progression via streamlined communication and aligned milestones across development and manufacturing phases
• Risk mitigation through our structured tech transfer protocol, ensuring process robustness before scale-up
• Operational continuity maintained by BioDuro’s resident technical teams who bridge the gap between R&D and manufacturing, enabling rapid issue resolution and continuous process optimization

This structure empowers clients to maintain strategic focus on their core science while relying on a coordinated, accountable partnership for execution excellence.

Q3: How does the joint venture ensure quality and regulatory readiness?

Quality and regulatory alignment are architected into the partnership’s DNA through a joint QA governance framework and harmonized project management structure. This unified approach standardizes documentation protocols, quality systems, and regulatory strategies across both organizations.

Cenra contributes a strong track record of successful inspections by leading global regulatory agencies including the U.S. FDA, EMA, PMDA, and TFDA—demonstrating consistent compliance with international GMP standards.

Additionally, BioDuro’s on-site technical presence during manufacturing ensures that analytical methods and process parameters developed in our labs are faithfully executed and continuously monitored in Cenra’s production environment, creating a closed-loop quality system that spans development through commercial supply.

Q4: What manufacturing capabilities does Cenra bring to the partnership?

Cenra provides world-class GMP manufacturing infrastructure, featuring multiple cGMP production lines for both chemical synthesis and microbial fermentation. The facility accommodates flexible batch sizing—from pilot-scale production to large commercial volumes—with total reactor capacity exceeding hundreds of kiloliters.

These capabilities enable programs developed with BioDuro to scale efficiently and predictably into clinical and commercial manufacturing, supported by:

• Advanced process analytical technology (PAT) integration
• Robust supply chain management for raw materials and intermediates
• Comprehensive environmental, health, and safety (EHS) systems

BioDuro’s embedded technical teams ensure that process knowledge is preserved and enhanced throughout the scale-up journey, rather than lost in translation.

Q5: What types of molecules and technologies can the BioDuro–Cenra platform support?

The joint platform supports a broad spectrum of therapeutic modalities, including:

• Small molecules (complex chemical synthesis)
• Peptides (solid-phase and solution-phase synthesis)
• Fermentation-derived products (recombinant proteins, natural products, biosynthetic intermediates)

Technical capabilities span:

• Complex multi-step chemical synthesis and route optimization
• Biocatalysis and enzymatic transformations
• Fermentation process development and strain/metabolic engineering
• Advanced downstream purification and isolation technologies
• Analytical method development, validation, and stability studies

This technical breadth, combined with our integrated Developer-Receiver model and on-site technical support, allows the partnership to advance diverse therapeutic programs across all stages of development—from preclinical supply through commercial launch and lifecycle management.